Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status ; volume:13 ; number:1 ; day:26 ; month:7 ; year:2021 ; pages:1-10 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (26.7.2021), 1-10, 12.2021

Creator: Babapour Mofrad, Rosha
Scheltens, Philip
Kim, SangYun
Kang, Sungmin
Youn, Young Chul
An, Seong Soo A.
Tomassen, Jori
Berckel, Bart N. M. van
Visser, Pieter Jelle
Flier, Wiesje M. van der
Teunissen, Charlotte E.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-021-00873-w

URN: urn:nbn:de:101:1-2021102408113571579524

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Babapour Mofrad, Rosha
Scheltens, Philip
Kim, SangYun
Kang, Sungmin
Youn, Young Chul
An, Seong Soo A.
Tomassen, Jori
Berckel, Bart N. M. van
Visser, Pieter Jelle
Flier, Wiesje M. van der
Teunissen, Charlotte E.
SpringerLink (Online service)

Other Objects (12)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

Investigation of oligomerization of amyloid-β and prion protein

Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Origins of amyloid-β

Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases

Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Related objects

Reset password